Form 4 for PCRX Pacira BioSciences, Inc.
Accepted 2023-06-16 00:00:00 ET · period of report 2023-06-14 · accession 0001209191-23-038023 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2023-06-16 | 2023-06-14 | PCRX | HASTINGS PAUL J | Dir | A - Grant | $0.00 | +1,775 | 8,374 | +27% | $0 |
| D | 2023-06-16 | 2023-06-14 | PCRX | HASTINGS PAUL J | Dir | A - Grant | $0.00 | +12.9K | 12.9K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-06-14 | A | A | 1,775 | $0.00 | 8,374 | D | — | — | (F1) Represents restricted stock units that vest on June 3, 2024, provided that the reporting person remains in continuous service with the issuer through the vesting date. Each restricted stock unit represents the contingent right to receive one share of the issuer's common stock. |
| 2 | Derivative | Stock Option (Right to Buy) | 2023-06-14 | A | A | 12,925 | $0.00 | 12,925 | D | $38.74 · 2024-06-14 to 2033-06-14 | 12,925 Common Stock |